Clinical Effect of Panfoxol of Otolaryngological Diseases of Upper Respiratory Tract Infection: A Multicenter Retrospective Observational Study
Condition: Otologic Disease
MeSH terms: Infections; Respiratory Tract Infections; Otorhinolaryngologic Diseases; Ear Diseases
Study type: Interventional

Summary: 
      Patients with otolaryngological diseases caused by upper respiratory tract infections,
      including allergic rhinitis, chronic rhinosinusitis, secretory otitis media, and oblate gland
      hypertrophy, were treated with all drugs from Sun Yat-sen Memorial Hospital of Sun Yat-sen
      University, the First Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial
      People's Hospital, and Guangdong Provincial Hospital of Traditional Chinese Medicine from
      January 2021 to December 2022. According to the treatment methods, the patients were divided
      into panfosol + conventional treatment group and conventional treatment group for multicenter
      retrospective analysis.
    

Detailed description: 
      FIrstly, Data of all patients were collected before and after treatment, including nasal
      endoscopy Lund Kennedy score, VAS scale for nasal/facial/olfactory symptoms, and
      ear/nose/snoring VAS scale, etc. According to the change values before and after treatment,
      the treatment results were divided into cure (complete control of the disease), effective
      (partial control of the disease), ineffective (uncontrolled disease). secondly, All
      participants were reviewed for gastrointestinal disturbances (nausea, abdominal pain,
      vomiting), skin reactions (rash, urticaria), respiratory discomfort (cough, dyspnea, asthma),
      and common problems (fever, fatigue, allergic reactions) after medication.
    

Intervention name(s): Panfoshu+Conventional Treatment（program-A）; Panfoshu+Conventional Treatment（program-B）; Conventional Treatment
Intervention type(s): Drug; Drug; Other
Intervention description(s): On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken orally once a day on an empty stomach, one capsule at a time. 1 course of treatment was 6mon, which was taken 10 days a month, stopped for 20 days for 3 months, and observed for another 3 months(unmedicated). Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.; On the basis of conventional treatment, panfoshu combined therapy was added.Panfoshu was taken for 30 days in the first month, stopped in the second month, taken for 10 days and stopped for 20 days in a row for 3 months, and finally observed for 1 month. Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.; Patients in this group were treated with only the conventional treatment.
Other intervention name(s): Bacteriolysis product; Bacteriolysis product
Allocation: Non-Randomized
Intervention model: Factorial Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Panfoxol; Otologic Disease; Curative Effect; Upper Respiratory Tract Infection (URTI)